NRx Pharmaceuticals, Inc (NRXP) - Rentabilitas dodolan reged

Simbol resmi perusahaan NRx Pharmaceuticals Inc. (NRXP)

Liquidity shortages and asset restructuring create serious challenges for NRx Pharmaceuticals (NRXP). The estimated gross margin, reacting to Fed policy, is fixed at 25.20, signaling risks in the event of a trend reversal. The firm's stability is based on the development of therapies for severe psychiatric conditions, and the business's success depends on regulatory approval of the drug NRX-101.

NRXP (NRx Pharmaceuticals, Inc) riwayat Rentabilitas reged saka 04.07.2022 nganti 20.11.2026

Rincian metrik keuangan lan pasar NRx Pharmaceuticals, Inc (NRXP)

- rega saham lan target rega konsensus:
Analisis dhasar perusahaan:NRx Pharmaceuticals Inc. (NRXP)
Produk sing diprodhuksi NRx Pharma

Gross margin measures production efficiency by capturing the portion of revenue remaining after deducting direct product creation costs. By analyzing the gross margin history, an investor assesses the ability of NRx Pharmaceuticals (NRXP) to balance drug synthesis automation against the high costs of recruiting psychiatrists for clinical trials, which directly determines the stability of the company's operating profit.